SLC5A2 and diabetes mellitus: An umbrella review of meta-analyses of 32 trials including a total of 55,283 participants with T2DM, pre-diabetes, or high risk of diabetes indicated that SGLT2-is are associated with a 13% risk reduction in MACE (relative risk [RR], 0.87; 95%CI, 0.82–0.93) (Zhu et al., 2020).